PL360280A1 - Use of baculovirus vectors in gene therapy - Google Patents

Use of baculovirus vectors in gene therapy

Info

Publication number
PL360280A1
PL360280A1 PL36028001A PL36028001A PL360280A1 PL 360280 A1 PL360280 A1 PL 360280A1 PL 36028001 A PL36028001 A PL 36028001A PL 36028001 A PL36028001 A PL 36028001A PL 360280 A1 PL360280 A1 PL 360280A1
Authority
PL
Poland
Prior art keywords
gene therapy
baculovirus vectors
baculovirus
vectors
therapy
Prior art date
Application number
PL36028001A
Other languages
English (en)
Polish (pl)
Inventor
Seppo Yla-Herttuala
Kari J. Airenne
Original Assignee
Ark Therapeutics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ark Therapeutics Limited filed Critical Ark Therapeutics Limited
Publication of PL360280A1 publication Critical patent/PL360280A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL36028001A 2000-05-26 2001-05-29 Use of baculovirus vectors in gene therapy PL360280A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0012997.3A GB0012997D0 (en) 2000-05-26 2000-05-26 Gene delivery
PCT/GB2001/002383 WO2001090390A1 (fr) 2000-05-26 2001-05-29 Utilisation de vecteurs de baculovirus en therapie genique

Publications (1)

Publication Number Publication Date
PL360280A1 true PL360280A1 (en) 2004-09-06

Family

ID=9892534

Family Applications (1)

Application Number Title Priority Date Filing Date
PL36028001A PL360280A1 (en) 2000-05-26 2001-05-29 Use of baculovirus vectors in gene therapy

Country Status (13)

Country Link
EP (1) EP1283894A1 (fr)
JP (1) JP2003533992A (fr)
KR (1) KR20030072213A (fr)
CN (1) CN1430675A (fr)
AU (1) AU2001258657A1 (fr)
CA (1) CA2413326A1 (fr)
GB (1) GB0012997D0 (fr)
HU (1) HUP0302119A3 (fr)
IL (1) IL153070A0 (fr)
MX (1) MXPA02011517A (fr)
NO (1) NO20025657D0 (fr)
PL (1) PL360280A1 (fr)
WO (1) WO2001090390A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1392837A2 (fr) * 2001-05-29 2004-03-03 Ark Therapeutics Limited Transfert genique de vecteur viral
AU2005319099B2 (en) 2004-02-02 2010-09-16 Ambrx, Inc. Modified human growth hormone
GB2429207A (en) 2004-02-02 2007-02-21 Ambrx Inc Modified human interferon polypeptides and their uses
KR101699142B1 (ko) 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
DK1828224T3 (en) 2004-12-22 2016-07-18 Ambrx Inc Compositions containing, methods including, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES
EP1836298B1 (fr) 2004-12-22 2012-01-18 Ambrx, Inc. Compositions de synthetase d'aminoacyl-arnt et utilisations correspondantes
US8080391B2 (en) 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
US7816320B2 (en) 2004-12-22 2010-10-19 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
ATE529442T1 (de) 2005-06-03 2011-11-15 Ambrx Inc Verbesserte humane interferon-moleküle und ihre verwendungen
PT2339014E (pt) 2005-11-16 2015-10-13 Ambrx Inc Métodos e composições compreendendo aminoácidos não-naturais
DK2615108T3 (en) 2006-09-08 2017-01-30 Ambrx Inc Modified human plasma polypeptide or fc scaffolds and their applications
WO2008030614A2 (fr) 2006-09-08 2008-03-13 Ambrx, Inc. Transcription d'arnt suppresseur dans des cellules de vertébrés
KR20140012199A (ko) 2007-03-30 2014-01-29 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
CN103965347B (zh) 2007-05-02 2017-07-18 Ambrx公司 经修饰干扰素β多肽和其用途
AU2008326324B9 (en) 2007-11-20 2012-11-15 Ambrx, Inc. Modified insulin polypeptides and their uses
EP3103880A1 (fr) 2008-02-08 2016-12-14 Ambrx, Inc. Polypeptides d'insuline modifiés et utilisations de ceux-ci
UA118536C2 (uk) 2008-07-23 2019-02-11 Амбркс, Інк. Модифікований поліпептид бичачого гранулоцитарного колонієстимулювального фактора та його застосування
CN101358204B (zh) * 2008-08-29 2011-05-18 浙江理工大学 一种重组杆状病毒感染后细胞膜及细胞器膜蛋白的制备方法
EP3216800A1 (fr) 2008-09-26 2017-09-13 Ambrx, Inc. Polypeptides d'érythropoïétine animale modifiés et leurs utilisations
MX348657B (es) 2008-09-26 2017-06-21 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
NZ600363A (en) 2009-12-21 2014-07-25 Ambrx Inc Modified porcine somatotropin polypeptides and their uses
CN102753573A (zh) 2009-12-21 2012-10-24 Ambrx公司 经过修饰的牛促生长素多肽和其用途
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
BR112013003522B1 (pt) 2010-08-17 2021-05-25 Ambrx, Inc. polipeptídeos relaxina modificados compreendendo um aminoácido não codificado naturalmente, seu método de preparação e seu uso, bem como ácido nucleico e célula hospedeira
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
KR20240024362A (ko) 2014-10-24 2024-02-23 브리스톨-마이어스 스큅 컴퍼니 변형된 fgf-21 폴리펩티드 및 그의 용도
CN110637027A (zh) 2017-02-08 2019-12-31 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
CN114736929B (zh) * 2022-05-16 2023-06-09 睿征医药科技(武汉)有限公司 一种用于昆虫细胞中产生重组杆状病毒的组合物、方法及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100695590B1 (ko) * 1996-11-01 2007-03-14 아크 테라퓨틱스 리미티드 산화질소 또는 프로스타시클린 생산을 자극하는 약제의 치료학적 용도 및 전달 기구
DE19735593C2 (de) * 1997-08-15 1999-08-26 Hepavec Ag Fuer Gentherapie Hüllprotein-modifizierter Baculovirus-Vektor für die Gentherapie
JP2003527816A (ja) * 1998-07-24 2003-09-24 アバンテイス・フアルマ・エス・アー バキュロウイルス由来のベクター及び脊椎動物の神経細胞に核酸を導入するための該ベクターの使用

Also Published As

Publication number Publication date
CA2413326A1 (fr) 2001-11-29
IL153070A0 (en) 2003-06-24
AU2001258657A1 (en) 2001-12-03
HUP0302119A3 (en) 2005-12-28
NO20025657L (no) 2002-11-25
WO2001090390A1 (fr) 2001-11-29
JP2003533992A (ja) 2003-11-18
CN1430675A (zh) 2003-07-16
EP1283894A1 (fr) 2003-02-19
NO20025657D0 (no) 2002-11-25
HUP0302119A2 (hu) 2003-09-29
MXPA02011517A (es) 2004-01-26
WO2001090390A9 (fr) 2003-01-09
GB0012997D0 (en) 2000-07-19
KR20030072213A (ko) 2003-09-13

Similar Documents

Publication Publication Date Title
IL153070A0 (en) Use of baculovirus vectors in gene therapy
IL152549A0 (en) Vectors for ocular transduction and use thereof for genetic therapy
AU1194802A (en) DNA expression vectors and methods of use
AU2002367262A8 (en) Personal user agent
GB0003397D0 (en) Therapeutic agents
GB0004003D0 (en) Therapeutic agents
HUP0401903A3 (en) Improved use of et-743 in cancer thereapy
GB0005789D0 (en) Therapeutic agents
GB0003254D0 (en) Heterocyclic compounds and their therapeutic use
AU2002303261A8 (en) Gene brcc2 and diagnostic and therapeutic uses thereof
GB0000564D0 (en) Therapeutic agents
GB0119025D0 (en) Compounds and their therapeutic use
GB0018887D0 (en) Compound and their therapeutic use
GB0008966D0 (en) Vectors for gene therapy
GB2376943B (en) Compounds and their therapeutic use
GB0112237D0 (en) Compounds and their therapeutic use
TW423322U (en) Improved structure of massage pad
GB0017625D0 (en) Use of compounds in therapy
GB0030058D0 (en) Use of compounds in therapy
GB0012945D0 (en) Use of compounds in therapy
GB0024614D0 (en) Massage manipulation ball
GB0017028D0 (en) Peptides and their therapeutic use
GB0118627D0 (en) Use of compounds in therapy
GB0023473D0 (en) Therapeutic use and formulation
GB0018888D0 (en) Compounds and their therapeutic use

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)